Patient Advocacy - How to Navigate 2025’s Uneven Gains and the Mandate for Transparency

While this rise promises significant progress, it also ushers in new complexities, demanding greater transparency and challenging notions of genuine influence.

One of the most consequential developments in healthcare this year unfolded almost in the shadows: patient advocacy quietly moved towards becoming a driving force. With health equity still an urgent challenge, the global rise in patient influence could lead to a defining moment for patient access, shaping how decisions are made, ensuring that everyone gets the care they need. If scientific innovation defined the front half of the decade, the growing power of advocacy may well define the next.

Influence Moves Upstream

Across markets, patient organisations have become more sophisticated, more connected and more strategic. The most striking development is how many are now engaging far earlier in the journey – not reacting to decisions but actively influencing them. Their ambitions go deeper than awareness or support; for many, accelerating access is central to their mission. Large surveys (PatientView, Dec 2024–Mar 2025) confirm widespread collaboration, with groups increasingly representing patients to regulators and industry PatientView+1, actively shaping areas from trial design (endpoints, PROs) and recruitment strategies to benefit-risk framing and HTA (Health Technology Assessment) discussions. Industry trend pieces and conference coverage from 2024–2025 describe “embedding advocacy in R&D” as a growth area pharmasalmanac.com+1.

Low-and middle-income regions and some therapy areas, however, continue to lag, underscoring persistent disparities in advocacy’s reach.

A major part of that progress comes down to two long-overlooked fundamentals: human understanding and lived experience. In 2025, a new wave of patient-led initiatives signalled a shift. Co-created materials, community-designed communication, and culturally resonant education programmes began to close gaps, helping people participate in designing their own care pathways. These efforts also pushed health equity higher up the agenda, highlighting obstacles often invisible to policymakers.

While this sophistication is global, its impact remains notably uneven. Progress is strongest in regions like the U.S. and EU, where regulatory expectations and resources exist, and in high-profile therapeutic areas such as oncology, rare diseases, and HIV. Low-and middle-income regions and some therapy areas, however, continue to lag, underscoring persistent disparities in advocacy’s reach PatientView+1.

Policy Meets Patients

One of the most telling developments in 2025 was the formalisation of patient input. The FDA finalized and expanded its patient-focused drug-development (PFDD) guidance, providing clear direction for industry on collecting and utilizing patient experience data raps.org+1. Concurrently, European policy, driven by the EMA and new pharma legislation, emphasized patient access and inclusion in scientific assessments and policy decisions. National bodies, like the ABPI in the UK, published handbooks to support compliant industry-patient partnerships (2025) European Medicines Agency (EMA)+2abpi.org.uk+2, signalling a systemic shift.

Beyond guidance, a faint, but significant emergence of patient involvement in HTA was observed in Europe, with a handful of HTA bodies inviting patients into deliberations not as symbolic attendees, but as contributors whose insights influence the definition of value. This indicates a future where patient perspectives influence HTA decisions directly, making improving access a shared priority. The tone from governments shifted toward genuine patient collaboration, away from the paternalism that long sidelined patient voices. Advocacy-driven campaigns pairing lived experience with strategic clarity proved that when human stories are brought directly to decision-makers, action can be unlocked.

As patient influence grows, so too do critical questions surrounding its authenticity. The rise in engagement, while largely positive, is not without its challenges.

Navigating Nuances: The Mandate for Transparency and Equity

As patient influence grows, so too do critical questions surrounding its authenticity. The rise in engagement, while largely positive, is not without its challenges. Concerns about commercial influence and potential conflicts of interest persist, with academic analyses and patient advocates cautioning that industry funding can sometimes risk biasing agendas or compromising independence if not managed with robust governance and transparency OUP Academic+1.

A crucial distinction exists between involvement and genuine influence. While involvement is up, influence, (defined by a measurable change in decisions or policies driven by patient groups), is more variable. Some interactions are consultative or PR-oriented rather than partnership-level OUP Academic. Often, patients are consulted late in development, a form of ‘tokenism’, rather than being integrated upstream in areas like target selection or trial design, limiting real impact clinicaltrialvanguard.com.

Capacity and equity gaps also remain; many grassroots organisations lack the resources or methodological know-how to engage effectively in complex debates like HTA modelling, creating an imbalance PatientView+1. Regulatory ambiguity and variable implementation of patient-centricity guidance across companies further complicate consistent, measurable impact raps.org+1.

The true test of influence, therefore, lies not just in involvement, but in measurable changes. Key indicators include documented protocol changes driven by patient input, patient-defined endpoints adopted in pivotal trials, inclusion of patient representatives with voting rights on governance committees, and HTA/coverage outcomes demonstrably linked to patient evidence and publicly disclosed partnership terms. These are derived from recent guidance and industry reporting trends raps.org+1. This shift from 'patient-centred' rhetoric to 'patient-powered' action demands a commitment to clear governance, open dialogue, and verifiable impact.

The future of access isn’t built by systems; it’s built by people and the systems that truly empower them.

Advocacy Goes Global

Make no mistake, this isn’t an isolated trend - it’s a global movement. Across Europe, North America, Africa and Asia-Pacific, advocacy groups are now sharing tactics, data, frameworks and expertise. They’re building coalitions that transcend borders and disease areas, professionalising, training, evaluating, and influencing at a scale rarely seen in the past. And they are doing it with one clear objective: turning scientific breakthroughs into real-world hope.

If 2025 was the year patient advocacy stepped into its power, 2026 will be the year that power becomes a true partner. The companies already listening, (and many are), will move further and faster by inviting patients not just into the conversation, but into the decisions, and crucially, by ensuring that involvement translates into measurable, transparent impact. That’s how access accelerates: by shifting from patient-centred to patient-powered. From system-led to human-first. Because the future of access isn’t built by systems; it’s built by people and the systems that truly empower them.

Next Steps for 2026: Catalyzing a Patient-Powered Ecosystem

To truly unlock the potential of patient advocacy and navigate its evolving landscape, all stakeholders have vital next steps. For pharmaceutical companies, this means moving beyond mere consultation to genuine co-design, involving patients earlier (ideally at the protocol concept stage) and empowering them with meaningful decision-making roles clinicaltrialvanguard.com, while also transparently publishing clear partnership agreements, funding disclosures, and metrics for impact abpi.org.uk. Patient advocacy groups, in turn, must continue to invest in their methodological capacity, understanding clinical outcomes, HTA, and Real-World Evidence. Or they can forge strategic partnerships with neutral academic centres PatientView+1,all while negotiating written terms that rigorously protect their independence.

Finally, regulators and HTA bodies are crucial in operationalising patient-focused drug development (PFDD) guidance, translating it into concrete submission templates and publicly sharing examples to provide clear blueprints for meaningful industry and patient group input raps.org. This collective commitment will be instrumental in building truly equitable, transparent, and patient-powered healthcare for the future.

Patient advocacy is more involved and more influential than it was five years ago, backed by regulatory guidance, industry handbooks, and widespread reported collaboration. But real decision-making power is still inconsistent and depends on transparency, resources, and whether engagement is genuinely co-creative rather than transactional PatientView+2raps.org+2.